ROBK, RNGC, IMSU, GLXZ, RYSMF, POSE, HMNC
– BOCL Up As Much As 47%
– SELR Up As Much As 196%
– ARIS Up As Much As 111%
These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.
|StockGuru Spotlight||Symbol||Spotlight Price||High||Up As Much As||Market Cap|
|October 20, 2011||SELR||$0.06||$0.17||196%||$5.78M|
|October 26, 2011||CTIX||$0.34||$0.70||106%||$61.30M|
|October 21, 2011||ARIS||$0.66||$1.39||111%||$10.30M|
|November 17, 2011||BOCL||$0.17||$0.25||47%||$296.25K|
|October 14, 2011||ZORM||$0.22||$0.33||50%||$12.74M|
|October 14, 2011||VCLD||$0.07||$0.10||54%||$6.49M|
Cellceutix Corporation (OTCBB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions. The Company reported on November 7, 2011, that it filed its Investigational New Drug (IND) application for Kevetrin(TM), a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating the clinical trial. During this time, the FDA reviews the data in the IND and determines the conditions under which human trials can commence. The Phase I trial is planned to take place at Dana-Farber Cancer Institute and its partner hospitals including Beth Israel Deaconess Medical Center. The clinical trial will test Kevetrin(TM) against a variety of different cancer types in patients with advanced-stage cancers. Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.
There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.
StockGuru is in its Ninth Year!